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Abstract InXiximab is a monoclonal antibody directed
against TNF-. It has been approved for use in rheumatoid
arthritis, ankylosing spondylitis, inXammatory bowel dis-
ease, psoriatic arthritis and plaque-type psoriasis. In case
reports, positive eVects on pustular variants of psoriasis
have also been reported. However, paradoxically, manifes-
tation of pustular psoriasis and plaque-type psoriasis has
been reported in patients treated with TNF antagonists
including inXiximab for other indications. Here, we report
on 5 patients with chronic plaque-type psoriasis who
developed palmoplantar pustulosis during or after discon-
tinuation of inXiximab therapy. In two of the Wve cases,
manifestation of palmoplantar pustulosis was not accom-
panied by worsening of plaque-type psoriasis. Possibly,
site-speciWc factors or a diVerential contribution of immu-
nological processes modulated by TNF inhibitors to pal-
moplantar pustulosis and plaque-type psoriasis may have
played a role.
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Introduction
Increased expression of TNF- has been identiWed as an
important pathophysiological mechanism in diVerent types
of chronic inXammation including psoriasis and psoriatic
arthritis. The knowledge about the central role of TNF- in
certain diseases has successfully been converted to the ther-
apeutic level; over the last years TNF antagonizing agents
such as the anti-TNF directed antibodies inXiximab and
adalimumab and the fusion protein etanercept have sub-
stantially improved the treatment of some of the most com-
mon chronic inXammatory conditions such as rheumatoid
arthritis (RA). With 80% of the patients reaching at least a
75% reduction of their baseline skin symptoms after
10 weeks of therapy [14], inXiximab is regarded as one of
the most potent agents available at present for the treatment
of psoriasis vulgaris. Other variants of psoriasis, such as
pustular psoriasis have not been formally tested in larger
clinical trials. However, in individual reports, positive
eVects of inXiximab on generalized pustular psoriasis
(GPP) with dramatic improvements in some cases have
been reported [3, 13, 15]. Because this type of pustular pso-
riasis is believed to correspond to an extreme activation of
psoriatic disease mechanisms, the high bioavailability of
inXiximab and its rapid onset of action following intrave-
nous infusion have been used to explain the surprisingly
fast decrease of pustule formation in patients treated with
the agent. Paradoxically, on the other hand, manifestation
of pustular psoriasis has been reported in patients treated
with TNF antagonists including inXiximab for other indica-
tions.
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Palmoplantar pustulosis (PPP) has long been regarded as
a localized variant of pustular psoriasis, although more
recent epidemiological and genetic Wndings argue against
this concept [2, 12]. Here, we report on Wve patients with
chronic plaque-type psoriasis who developed PPP during or
after discontinuation of inXiximab therapy.
Cases and discussion
Relevant aspects of the Wve patients with chronic plaque-
type psoriasis who developed PPP during or after discontin-
uation of inXiximab therapy are presented in the Table 1
and Fig. 1.
To the best of our knowledge, the development of PPP
during the treatment of plaque-type psoriasis with inXix-
imab has not yet been reported. The occurrence of pustular
skin lesions usually resembling GPP or palmoplantar pustu-
lar psoriasis has occasionally been observed in patients
treated with inXiximab for other indications [1, 6, 11, 16–
19]. Induction of pustular skin lesions seems not to be lim-
ited to inXiximab therapy, but has also been described in
association with the use of the TNF-antagonists etanercept
and adalimumab, including the use in one patient with
plaque-psoriasis treated with etanercept [4, 8–10, 16]. One
patient with seropositive RA developed GPP as well as PPP
during treatment with inXiximab [11]. This patient later
experienced a relapse of PPP when treatment with etaner-
cept was initiated, which also suggests that a class eVect of
TNF-antagonists may play a role.
In two of the three cases in whom an exacerbation of
plaque-psoriasis occurred parallel to the manifestation of
Table 1 Description of cases
PPP Pustulosis palmoplantaris, GPP Generalized pustular psoriasis, PV Psoriasis vulgaris, e.o.w Every other week
a Loss of >50% of maximum PASI response or increase of physician’s global assessment (PGA) by ¸ 2
b All patients received additional topical therapy with glucocorticosteroids and Vitamin D analogues
c Improvement rated by PGA with “almost clear” (PGA = 1)
d Week of inXiximab treatment
e BIW = twice weekly
f PASI 75 = Reduction in the psoriasis area and severity index (PASI) by ¸75%
Case 1 2 3 4 5
Sex Male Male Female Female Male
Age 37 42 67 30 41
Disease duration (years) 17  28 30 Unknown 15
Psoriasis type Plaque Plaque Plaque Plaque Plaque
Prior pustular psoriasis No No No No No
Psoriatic arthritis Yes No No No Yes
Familiy history of psoriasis Negative Positive Negative Unknown Negative
Prior UV-therapy Yes Yes Yes Yes Yes
Prior systemic therapies Methotrexate
LeXunomide
Etanercept
Prednisolone
Fumaric acid esters
Cyclosporine
Fumaric 
acid esters
Fumaric acid esters
Cyclosporine
Retinoids
Methotrexate
Fumaric acid esters
Cyclosporine
Methotrexate
Initial response to inXiximab Excellentc PASI 75f PASI 75 PASI 75 PASI 75
Time of manifestation of PPP Week 38d 8 weeks after end 
of inXiximab treatment
Week 3d Week 22d Week 40d
Concomitant worsening 
of plaque psoriasisa
Yes Yes No No Yes
Development of GPP 
in addition to PPP
Yes No No No No
Potential trigger factors of PPP
Infection prior to PPP Yes No Yes No No
Present smoking No No Yes (36 packyears) Unknown Unknown
Discontinuation of inXiximab Yes Yes Yes No Yes
Systemic therapy with suYcient 
control of PV and PPPb
Adalimumab 
40 mg e.o.w
Etanercept 25 mg 
BIW plus methotrexate 
7.5 mg/week orally
PUVA-therapy 
of palms and soles
(Additional 
topical therapy)
Etanercept 
50 mg BIW
Systemic therapy that failed 
to control PV or PPP
Etanercept 50 mg BIWe 
plus methotrexate 
15 mg/week orally
Etanercept 
25 mg BIWArch Dermatol Res (2008) 300:101–105 103
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PPP, typical trigger factors for active psoriasis could be
identiWed such as an infection (case 3) and the abrupt termi-
nation of anti-psoriatic treatment (case 2). These two cases
are compatible with the existence of common trigger fac-
tors for plaque psoriasis and PPP. What are other factors
that might contribute to the development of PPP during
treatment of psoriasis vulgaris? While the exact etiology of
PPP remains to be established, a history of smoking is the
most important known risk factor for PPP. However, only
one out of the three patients in whom a smoking history had
been obtained was a smoker at the time of onset of pustular
psoriasis (case 3). Streptococcal infection, a known risk
factor for psoriasis vulgaris, has not been established as a
risk factor for PPP and probably plays a minor role there.
However, in the cases presented here, one patient (case 3)
suVered an upper respiratory tract infection a few days
before manifestation of PPP, while another patient (case 1)
had suVered from a persistent cold 6 weeks before manifes-
tation of pustules. In the former patient, the close temporal
relationship between infectious symptoms and manifesta-
tion of PPP may point to a possible contribution of the
infection to triggering PPP, and a modulation of the
immune response to inXiximab appears possible.
It is likely that beyond the contribution of known risk
factors, other, immunological mechanisms may be involved
in the manifestation of PPP under inXiximab therapy. Inter-
feron (IFN)- has been suggested as a cytokine mediating
the manifestation of psoriasiform lesions in patients treated
with TNF-inhibitors as a consequence of crosstalk of TNF-
 and IFN-: TNF- is known to suppress the generation of
plasmacytoid dendritic cells that are very potent producers
of IFN-. Appearance of plasmacytoid dendritic cells (and
IFN-) in ths skin is considered to be an early and crucial
step in the pathogenesis of psoriasis (reviewed in [7]).
Thus, in patients treated with TNF-antagonists, the inhibi-
tion of TNF- might induce an increase of IFN- in the skin
favoring the manifestation of psoriasiform dermatitis. In
fact, an increase of IFN- signaling has been shown in
biopsy specimens from psoriatic plaques induced by TNF-
inhibitors compared with traditional psoriatic plaques [6].
The relevance of IFN- for PPP and TNF-inhibitor induced
PPP, however, still needs to be determined. The observa-
tion of an improvement of pre-existing psoriasis plaques
parallel to the Wrst manifestation of PPP in two of the cases
described here supports the concept that immunological
mechanisms and/or local factors are not identical in the
pathogenesis of plaque-type psoriasis and PPP. DiVerences
in pathogenesis between plaque psoriasis and PPP are also
supported by their diVerent genetic background, with
plaque psoriasis, but not PPP being linked to PSORS1, the
Fig. 1 Clinical picture of pustu-
losis palmoplantaris in patient 3 
with pustules in diVerent stages 
of evolution on a sharply delin-
eated erythematous lesion on the 
left sole (a) and yellowish pus-
tules on the left palm (b). Histo-
logical examination showing 
intraepidermal vesiculopustular 
dermatitis (c, H.E. stain of a bi-
opsy from the left plantar arch) 
with intraepidermal accumula-
tion of neutrophils and subcor-
neal pustule formation (d)104 Arch Dermatol Res (2008) 300:101–105
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major susceptibility locus for plaque-type psoriasis located
on 6p21 [2]. The localized nature of the pustules on palms
and soles occurring in association with inXiximab therapy
in some patients suggests a contribution of site-speciWc fac-
tors. Possibly, eccrine sweat glands that are numerous in
the palmoplantar location are involved in these processes.
Changes secondary to binding of inXiximab to TNF-, that
has been shown to be expressed in eccrine sweat glands,
have been suggested as a possible mechanism [11].
Withdrawal or dose reduction of systemic cyclosporine
and systemic or topical glucocorticosteroids given for treat-
ment of psoriasis vulgaris have been associated with mani-
festation of GPP, but not with PPP. To the best of our
knowledge, no reports on manifestation of GPP or PPP
associated with treatment with methotrexate, another drug
frequently used in the therapy of psoriasis, exist. However,
in the clinical trials with the CD11a-antagonist efalizumab
in the indication plaque psoriasis, development of PPP has
also been observed in 0.2% of 1,620 patients during the Wrst
12 weeks of treatment with efalizumab, compared to none
of the 715 patients in the placebo groups [5].
Whether therapy with TNF-antagonists may induce a
more severe form of plaque psoriasis or psoriatic arthritis in
some patients treated for these indications is diYcult to
determine, as the natural course of both plaque psoriasis
and psoriatic arthritis is variable and a loss of eVect is not
easily diVerentiated from an induction of a more severe
form of the respective disease. However, as a manifestation
of plaque psoriasis has been noted in a number of patients
treated with TNF-antagonists for other indications without
a personal or family history of psoriasis [6, 16], it is likely
that TNF-antagonists may in some individuals and proba-
bly in conjunction with environmental factors favor mani-
festation or worsening of psoriatic skin and/or bone disease.
The treatment of patients with plaque-psoriasis develop-
ing PPP should be decided on an individual basis. In case
plaque-psoriasis remains controlled under inXiximab ther-
apy, addition of topical therapy may be suYcient for treat-
ment of PPP in some instances (case 4). However, in some
cases, additional topical therapy may not be suYcient and
UV-therapy or another systemic therapy may be necessary
in addition to or as replacement of inXiximab therapy (case
3). When manifestation of PPP is accompanied by worsen-
ing of plaque-psoriasis, discontinuation of inXiximab ther-
apy is advisable and initiation of other systemic
antipsoriatic agents, such as cyclosporine or a diVerent
TNF-antagonist, may be necessary (cases 1 and 5).
In summary, pustular psoriasis may show a good
response to treatment with TNF-antagonists such as inXix-
imab. However, pustular psoriasis may also manifest dur-
ing treatment of rheumatological diseases, and, as
described here, also in patients with plaque-type psoriasis
under treatment with inXiximab. Manifestation of PPP
under inXiximab is not necessarily accompanied by wors-
ening of pre-existing plaque psoriasis. Management of the
pustular skin lesions has to be decided on an individual
basis. In a subgroup of patients, therapy with the TNF-
antagonist has to be discontinued and another systemic
therapy (including a diVerent TNF-antagonist) will proba-
bly be necessary to suYciently control plaque-psoriasis and
PPP.
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